{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:13:59Z","timestamp":1794334439479,"version":"4.9.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94020-2","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T13:37:37Z","timestamp":1742045857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Tomoaki","family":"Takata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosuke","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Mae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Iyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Isomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"94020_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10157-009-0199-x","volume":"13","author":"E Imai","year":"2009","unstructured":"Imai, E. et al. Prevalence of chronic kidney disease in the Japanese general population. Clin. Exp. Nephrol. 13, 621\u2013630 (2009).","journal-title":"Clin. Exp. Nephrol."},{"key":"94020_CR2","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10157-021-02049-0","volume":"25","author":"K Nagai","year":"2021","unstructured":"Nagai, K., Asahi, K., Iseki, K. & Yamagata, K. Estimating the prevalence of definitive chronic kidney disease in the Japanese general population. Clin. Exp. Nephrol. 25, 885\u2013892 (2021).","journal-title":"Clin. Exp. Nephrol."},{"key":"94020_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000445844","volume":"134","author":"M Cortinovis","year":"2016","unstructured":"Cortinovis, M., Ruggenenti, P. & Remuzzi, G. Progression, remission and regression of chronic renal diseases. Nephron 134, 20\u201324 (2016).","journal-title":"Nephron"},{"key":"94020_CR4","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.3390\/ijms22094374","volume":"22","author":"T Takata","year":"2021","unstructured":"Takata, T. & Isomoto, H. Pleiotropic effects of sodium-glucose Cotransporter-2 inhibitors: Renoprotective mechanisms beyond glycemic control. Int. J. Mol. Sci. 22, 4374 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"94020_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21010190","volume":"21","author":"K Hosokawa","year":"2019","unstructured":"Hosokawa, K. et al. Ipragliflozin ameliorates endoplasmic reticulum stress and apoptosis through preventing ectopic lipid deposition in renal tubules. Int. J. Mol. Sci. 21, 1\u201312 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"94020_CR6","doi-asserted-by":"publisher","first-page":"18466","DOI":"10.1038\/s41598-024-69420-5","volume":"14","author":"Y Kim","year":"2024","unstructured":"Kim, Y. et al. Impact of hyperuricemia on CKD risk beyond genetic predisposition in a population-based cohort study. Sci. Rep. 14, 18466 (2024).","journal-title":"Sci. Rep."},{"key":"94020_CR7","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1097\/HJH.0000000000001825","volume":"36","author":"S Borrelli","year":"2018","unstructured":"Borrelli, S. et al. Short-term blood pressure variability in nondialysis chronic kidney disease patients: Correlates and prognostic role on the progression of renal disease. J. Hypertens. 36, 2398\u20132405 (2018).","journal-title":"J. Hypertens."},{"key":"94020_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230020","volume":"15","author":"M Provenzano","year":"2020","unstructured":"Provenzano, M. et al. Renal resistive index in chronic kidney disease patients: Possible determinants and risk profile. PLoS One 15, e0230020 (2020).","journal-title":"PLoS One"},{"key":"94020_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240402","volume":"15","author":"T Sofue","year":"2020","unstructured":"Sofue, T. et al. Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One 15, e0240402 (2020).","journal-title":"PLoS One"},{"key":"94020_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2369-12-31","volume":"12","author":"M Kawashima","year":"2011","unstructured":"Kawashima, M., Wada, K., Ohta, H., Terawaki, H. & Aizawa, Y. Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: A long-term retrospective cohort study. BMC Nephrol. 12, 31 (2011).","journal-title":"BMC Nephrol."},{"key":"94020_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2215\/CJN.04271007","volume":"3","author":"ET Rosolowsky","year":"2008","unstructured":"Rosolowsky, E. T. et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin. J. Am. Soc. Nephrol. 3, 706\u2013713 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"94020_CR12","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1093\/ndt\/gfq740","volume":"26","author":"IZ Ben-Dov","year":"2011","unstructured":"Ben-Dov, I. Z. & Kark, J. D. Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: The Jerusalem Lipid Research Clinic cohort study. Nephrol. Dial. Transplant. 26, 2558\u20132566 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"94020_CR13","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1681\/ASN.2008010080","volume":"19","author":"RP Obermayr","year":"2008","unstructured":"Obermayr, R. P. et al. Elevated uric acid increases the risk for kidney disease. J. Am. Soc. Nephrol. 19, 2407\u20132413 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"94020_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.exger.2008.01.006","volume":"43","author":"G Sturm","year":"2008","unstructured":"Sturm, G. et al. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp. Gerontol. 43, 347\u2013352 (2008).","journal-title":"Exp. Gerontol."},{"key":"94020_CR15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10157-021-02042-7","volume":"25","author":"K Tada","year":"2021","unstructured":"Tada, K. et al. Association between serum uric acid and new onset and progression of chronic kidney disease in a Japanese general population: Iki epidemiological study of atherosclerosis and chronic kidney disease. Clin. Exp. Nephrol. 25, 751\u2013759 (2021).","journal-title":"Clin. Exp. Nephrol."},{"key":"94020_CR16","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1038\/s41598-024-55809-9","volume":"14","author":"Y Asahina","year":"2024","unstructured":"Asahina, Y. et al. Association between urinary uric acid excretion and kidney outcome in patients with CKD. Sci. Rep. 14, 5119 (2024).","journal-title":"Sci. Rep."},{"key":"94020_CR17","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","volume":"3","author":"K Ichida","year":"2012","unstructured":"Ichida, K. et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun. 3, 764 (2012).","journal-title":"Nat. Commun."},{"key":"94020_CR18","doi-asserted-by":"publisher","DOI":"10.5551\/jat.65087","author":"Y Kawachi","year":"2024","unstructured":"Kawachi, Y. et al. Effect of the xanthine oxidase inhibitor febuxostat on the cardio-ankle vascular index in asymptomatic patients with hyperuricemia and liver dysfunction: A sub-analysis of the PRIZE study. J. Atheroscler. Thromb. https:\/\/doi.org\/10.5551\/jat.65087 (2024).","journal-title":"J. Atheroscler. Thromb."},{"key":"94020_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/hr.2014.107","volume":"37","author":"Y Shibagaki","year":"2014","unstructured":"Shibagaki, Y., Ohno, I., Hosoya, T. & Kimura, K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens. Res. 37, 919\u2013925 (2014).","journal-title":"Hypertens. Res."},{"key":"94020_CR20","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea, M. et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol. 5, 1388\u20131393 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"94020_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12882-015-0047-z","volume":"16","author":"T Kanji","year":"2015","unstructured":"Kanji, T., Gandhi, M., Clase, C. M. & Yang, R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 16, 58 (2015).","journal-title":"BMC Nephrol."},{"key":"94020_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","volume":"66","author":"D Sircar","year":"2015","unstructured":"Sircar, D. et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: A 6-month, double-blind, randomized, placebo-controlled trial. Am. J. Kidney Dis. 66, 945\u2013950 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"94020_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/ndt\/gft378","volume":"29","author":"B Bose","year":"2014","unstructured":"Bose, B. et al. Effects of uric acid-lowering therapy on renal outcomes: A systematic review and meta-analysis. Nephrol. Dial. Transplant. 29, 406\u2013413 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"94020_CR24","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria, A. et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N. Engl. J. Med. 382, 2493\u20132503 (2020).","journal-title":"N. Engl. J. Med."},{"key":"94020_CR25","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve, S. V. et al. Effects of allopurinol on the progression of chronic kidney disease. N. Engl. J. Med. 382, 2504\u20132513 (2020).","journal-title":"N. Engl. J. Med."},{"key":"94020_CR26","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2008","unstructured":"Kimura, K. et al. Febuxostat therapy for patients with Stage 3 CKD and asymptomatic hyperuricemia: A randomized trial. Am. J. Kidney Dis. 72, 798\u2013810 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"94020_CR27","first-page":"1620","volume":"33","author":"HW Chou","year":"2018","unstructured":"Chou, H. W. et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: A 13-year inception cohort study. Nephrol. Dial. Transplant. 33, 1620\u20131627 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"94020_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejim.2023.04.025","volume":"113","author":"SW Lai","year":"2023","unstructured":"Lai, S. W., Liao, K. F., Kuo, Y. H., Hwang, B. F. & Liu, C. S. Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia. Eur. J. Intern. Med. 113, 91\u201397 (2023).","journal-title":"Eur. J. Intern. Med."},{"key":"94020_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/biomedicines11020567","volume":"11","author":"H Yanai","year":"2023","unstructured":"Yanai, H., Katsuyama, H., Hakoshima, M. & Adachi, H. Urate transporter 1 can be a therapeutic target molecule for chronic kidney disease and diabetic kidney disease: A retrospective longitudinal study. Biomedicines 11, 567 (2023).","journal-title":"Biomedicines"},{"key":"94020_CR30","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.2147\/DDDT.S416025","volume":"17","author":"K Yanai","year":"2023","unstructured":"Yanai, K. et al. The efficacy and safety of dotinurad on uric acid and renal function in patients with hyperuricemia and advanced chronic kidney disease: A Single Center, retrospective analysis. Drug Des. Develop. Ther. 17, 3233\u20133248 (2023).","journal-title":"Drug Des. Develop. Ther."},{"key":"94020_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s10157-023-02419-w","volume":"28","author":"O Kurihara","year":"2024","unstructured":"Kurihara, O., Yamada, T., Kato, K. & Miyauchi, Y. Efficacy of dotinurad in patients with severe renal dysfunction. Clin. Exp. Nephrol. 28, 208\u2013216 (2024).","journal-title":"Clin. Exp. Nephrol."},{"key":"94020_CR32","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"RJ Johnson","year":"2013","unstructured":"Johnson, R. J. et al. Uric acid and chronic kidney disease: Which is chasing which?. Nephrol. Dial. Transplant. 28, 2221\u20132228 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"94020_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.6212","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Target serum urate achievement and chronic kidney disease progression in patients with gout and kidney disease. JAMA Intern. Med. https:\/\/doi.org\/10.1001\/jamainternmed.2024.6212 (2024).","journal-title":"JAMA Intern. Med."},{"key":"94020_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.10.022","author":"B Ghang","year":"2024","unstructured":"Ghang, B. et al. Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2024.10.022 (2024).","journal-title":"Kidney Int."},{"key":"94020_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.ajkd.2020.09.009","volume":"77","author":"AG Stack","year":"2021","unstructured":"Stack, A. G. et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: A randomized trial. Am. J. Kidney Dis. 77, 481\u2013489 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"94020_CR36","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1681\/ASN.0000000000000326","volume":"35","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink, H. J. L. et al. Combination treatment with verinurad and allopurinol in CKD: A randomized placebo and active controlled trial. J. Am. Soc. Nephrol. 35, 594\u2013606 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"94020_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12882-024-03535-9","volume":"25","author":"H Amano","year":"2024","unstructured":"Amano, H., Kobayashi, S. & Terawaki, H. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease. BMC Nephrol. 25, 97 (2024).","journal-title":"BMC Nephrol."},{"key":"94020_CR38","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s10157-018-1586-y","volume":"22","author":"H Yu","year":"2018","unstructured":"Yu, H. et al. Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease: A prospective pilot study. Clin. Exp. Nephrol. 22, 1324\u20131330 (2018).","journal-title":"Clin. Exp. Nephrol."},{"key":"94020_CR39","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1681\/ASN.2020040523","volume":"31","author":"M Sellmayr","year":"2020","unstructured":"Sellmayr, M. et al. Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J. Am. Soc. Nephrol. 31, 2773\u20132792 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"94020_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.kint.2020.08.024","volume":"99","author":"T Bardin","year":"2021","unstructured":"Bardin, T. et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int. 99, 218\u2013226 (2021).","journal-title":"Kidney Int."},{"key":"94020_CR41","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.3390\/nu14194161","volume":"14","author":"CI Ciongradi","year":"2022","unstructured":"Ciongradi, C. I. et al. The impact of water and other fluids on pediatric nephrolithiasis. Nutrients. 14, 4161 (2022).","journal-title":"Nutrients."},{"key":"94020_CR42","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.1038\/s41598-025-87227-w","volume":"15","author":"J Wu","year":"2025","unstructured":"Wu, J. Association between dietary niacin intake and kidney stones in American adults. Sci. Rep. 15, 5666 (2025).","journal-title":"Sci. Rep."},{"key":"94020_CR43","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMoa035700","volume":"350","author":"HK Choi","year":"2004","unstructured":"Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W. & Curhan, G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N. Engl. J. Med. 350, 1093\u20131103 (2004).","journal-title":"N. Engl. J. Med."},{"key":"94020_CR44","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41598-025-85292-9","volume":"15","author":"X Dai","year":"2025","unstructured":"Dai, X., Chang, Y. & Hou, Y. Associations between the conicity index and kidney stone disease prevalence and mortality in American adults. Sci. Rep. 15, 902 (2025).","journal-title":"Sci. Rep."},{"key":"94020_CR45","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.2169\/internalmedicine.1342-22","volume":"63","author":"T Takata","year":"2024","unstructured":"Takata, T. & Isomoto, H. The versatile role of uromodulin in renal homeostasis and its relevance in chronic kidney disease. Intern. Med. 63, 1342\u20131422 (2024).","journal-title":"Intern. Med."},{"key":"94020_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/diseases13010007","volume":"13","author":"T Takata","year":"2025","unstructured":"Takata, T. et al. Advanced glycation end-product-modified heat shock protein 90 may be associated with urinary stones. Diseases 13, 7 (2025).","journal-title":"Diseases"},{"key":"94020_CR47","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/nep.14373","volume":"29","author":"F Assadi","year":"2024","unstructured":"Assadi, F. & Faghihi, T. A narrative review of monogenic disorders causing nephrolithiasis and chronic kidney disease. Nephrology 29, 781\u2013790 (2024).","journal-title":"Nephrology"},{"key":"94020_CR48","doi-asserted-by":"publisher","first-page":"107730","DOI":"10.1016\/j.isci.2023.107730","volume":"26","author":"Y Tanaka","year":"2023","unstructured":"Tanaka, Y. et al. URAT1 is expressed in cardiomyocytes and dotinurad attenuates the development of diet-induced metabolic heart disease. iScience 26, 107730 (2023).","journal-title":"iScience"},{"key":"94020_CR49","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan.pdf. Am. J. Kidney Dis. 53, 982\u2013992 (2009).","journal-title":"Am. J. Kidney Dis."},{"issue":"suppl","key":"94020_CR50","first-page":"1","volume":"44","author":"I Hisatome","year":"2020","unstructured":"Hisatome, I. et al. Japanese Society of gout and uric & nucleic acids 2019 Guidelines for Management of Hyperuricemia and Gout 3rd edition. Gout Uric Nucleic Acids 44(suppl), 1\u201340 (2020).","journal-title":"Gout Uric Nucleic Acids"},{"key":"94020_CR51","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul, F., Erdfelder, E., Buchner, A. & Lang, A. G. Statistical power analyzes using G*Power 3.1: Tests for correlation and regression analyses. Behav. Res. Methods 41, 1149\u20131160 (2009).","journal-title":"Behav. Res. Methods"},{"key":"94020_CR52","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1038\/s41598-022-15153-2","volume":"12","author":"H Kurumi","year":"2022","unstructured":"Kurumi, H. et al. Investigating the role of heat shock protein 47 in fibrosis in Crohn\u2019s disease. Sci. Rep. 12, 10966 (2022).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94020-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94020-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94020-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T01:24:15Z","timestamp":1742088255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94020-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94020"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94020-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8990"}}